CerMed Corporation to Present at Sachs Associates Third Annual European Global Lifescience Forum on February 11, 2010 in Zurich

MONTEREY, Calif.--(BUSINESS WIRE)--CerMed Corporation, www.cermedcorp.com, an international women’s healthcare medical device company that is commercializing three breakthrough products for cervical cancer screening and a women’s controlled barrier contraceptive that protects against infection from HIV, will be presenting at the Sachs Associates Third Annual European Global Lifescience Forum on February 11, 2010 at 14:15 Zurich time.

“CerMed’s second product under development is CerCap™ HIV, a barrier contraceptive cervical cap which reduces the risk of infection from HIV. CerCap™ is being developed through strategic partnerships with the University of California San Francisco, one of the leading hospitals in the field.”

Linda Masterson, President and Chief Operating Officer of CerMed, will be leading the presentation and will discuss CerMed’s products which address two major market segments, cervical cancer screening and contraceptive/sexually transmitted disease (STD) prevention.

Ms. Masterson said, “We are excited about the upcoming presentation which will provide us the platform to meet with key players in the health sciences field and introduce CerMed as an emerging company in the women’s healthcare arena. This conference also marks the first time CerMed will be presenting before an industry forum, and will provide us the opportunity to review CerMed’s product line and our commercialization plans.”

“We believe CerMed is the first company to bring a fundamentally different approach to the improvement of women’s cervical health. Our first product, CerMap™ Cervical Specimen Collection and Mapping System, will be marketed initially in China, where we already have SFDA clearance. We expect to market worldwide later this summer.”

“CerMap™ can be used as a front end for collection for the standard PAP analysis and will be used in conjunction with our Point of Care Cervical Cancer Screening Test System, as a replacement for the traditional Pap smear. This system is currently under development with Duke University and Innovative Micro Technology,” she continued. “The test system is designed as a primary screening system to replace the standard PAP. It is being designed to provide greater sensitivity and specificity than is currently available from the current standard of care. We believe this novel, low cost product can help save the lives of the half-million women who die from cervical cancer each year, generally because of errors in the current methods or lack of access to expensive laboratories and methods.”

She continued, “CerMed’s second product under development is CerCap™ HIV, a barrier contraceptive cervical cap which reduces the risk of infection from HIV. CerCap™ is being developed through strategic partnerships with the University of California San Francisco, one of the leading hospitals in the field.”

Ms. Masterson concluded, “With life-saving products ready to launch and others under development, we look forward to becoming an important player in women’s healthcare.”

About CerMed Corporation

CerMed Corporation, www.cermedcorp.com, is a privately owned international women’s healthcare company. CerMed is committed to improving the health of women worldwide by developing, manufacturing and marketing quality, high-value added medical products to prevent, diagnose and treat female reproductive system diseases. The Company focuses on two major markets: the cervical cancer screening market, an $18 billion market opportunity, and the market for a women’s controlled HIV contraceptive, a $52 billion market opportunity. CerMed is commercializing three innovative products which address significant limitations of currently available methods in these huge markets.

This press release contains forward-looking statements regarding future events and the future performance of CerMed, Corp. that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to completion of the financing, potential need for additional financing, manufacturing scale-up, completion of development for CerCap and the Cervical Cancer Screening Test System.

CerMap and CerCap are trademarks of CerMed Corporation